IRIS
ROMANO, ALESSANDRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.219
EU - Europa 5.550
AS - Asia 5.251
SA - Sud America 804
AF - Africa 712
Continente sconosciuto - Info sul continente non disponibili 318
OC - Oceania 6
Totale 22.860
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.850
SG - Singapore 2.490
RU - Federazione Russa 1.769
IT - Italia 1.562
CN - Cina 1.516
IE - Irlanda 690
BR - Brasile 640
CI - Costa d'Avorio 423
VN - Vietnam 411
UA - Ucraina 401
KR - Corea 287
CA - Canada 261
FR - Francia 239
GB - Regno Unito 165
SE - Svezia 165
DE - Germania 150
IN - India 119
NG - Nigeria 112
FI - Finlandia 93
BD - Bangladesh 82
PL - Polonia 65
AR - Argentina 63
SN - Senegal 62
MX - Messico 59
NL - Olanda 58
JP - Giappone 52
HK - Hong Kong 51
TR - Turchia 39
ZA - Sudafrica 37
ES - Italia 36
IQ - Iraq 35
BE - Belgio 26
CZ - Repubblica Ceca 26
BJ - Benin 25
ID - Indonesia 23
CL - Cile 21
UZ - Uzbekistan 21
EC - Ecuador 20
CO - Colombia 19
CH - Svizzera 18
IR - Iran 18
VE - Venezuela 16
MA - Marocco 15
AT - Austria 14
LT - Lituania 14
SA - Arabia Saudita 14
PK - Pakistan 13
GR - Grecia 12
LB - Libano 11
IL - Israele 10
PY - Paraguay 10
AE - Emirati Arabi Uniti 9
EG - Egitto 9
JM - Giamaica 9
JO - Giordania 9
DO - Repubblica Dominicana 8
RO - Romania 8
AL - Albania 7
KE - Kenya 7
PH - Filippine 7
PE - Perù 6
TN - Tunisia 6
AU - Australia 5
DZ - Algeria 5
GT - Guatemala 5
NO - Norvegia 5
SV - El Salvador 5
AZ - Azerbaigian 4
HR - Croazia 4
KZ - Kazakistan 4
NI - Nicaragua 4
PR - Porto Rico 4
TH - Thailandia 4
UY - Uruguay 4
BB - Barbados 3
EU - Europa 3
MY - Malesia 3
OM - Oman 3
PA - Panama 3
RS - Serbia 3
SI - Slovenia 3
BA - Bosnia-Erzegovina 2
BF - Burkina Faso 2
BG - Bulgaria 2
BO - Bolivia 2
BY - Bielorussia 2
CR - Costa Rica 2
CY - Cipro 2
DK - Danimarca 2
ET - Etiopia 2
HN - Honduras 2
KH - Cambogia 2
LU - Lussemburgo 2
LV - Lettonia 2
MT - Malta 2
NP - Nepal 2
SR - Suriname 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AO - Angola 1
Totale 22.523
Salva come PNG Salva come JPEG
Città #
Dallas 1.836
Singapore 1.496
Santa Clara 1.150
Moscow 813
San Jose 730
Dublin 682
Ashburn 583
Chandler 577
Jacksonville 443
Hefei 442
Chicago 430
Abidjan 423
Houston 391
Catania 323
Boardman 290
Seoul 286
Council Bluffs 251
Los Angeles 238
Beijing 221
Lauterbourg 189
Lawrence 143
Cambridge 141
New York 137
Andover 135
Nanjing 134
Ho Chi Minh City 132
Toronto 124
Civitanova Marche 113
Florence 107
Hanoi 86
São Paulo 78
Buffalo 72
Milan 72
Des Moines 71
Rome 65
Dakar 62
San Mateo 60
Abuja 56
Warsaw 55
Montreal 51
Wilmington 51
Hong Kong 48
Lagos 48
Washington 47
Dong Ket 45
Nanchang 45
Orem 44
Messina 43
Palermo 43
Tokyo 43
Helsinki 41
Saint Petersburg 41
Stockholm 38
London 37
Munich 36
Hebei 35
Brooklyn 33
Lappeenranta 33
Amsterdam 32
Poplar 31
Seattle 31
Tianjin 31
Ottawa 30
Shenyang 29
Grafing 28
Atlanta 27
Phoenix 26
Boston 25
Cotonou 25
Denver 25
Brussels 23
Johannesburg 23
Jiaxing 21
Naples 21
Paris 21
The Dalles 21
Mexico City 20
Rio de Janeiro 20
Ankara 19
Bremen 19
Chennai 19
Columbus 19
Mumbai 19
San Francisco 19
Turku 19
Changsha 18
Kochi 18
Baghdad 16
Charlotte 16
Frankfurt am Main 15
Tehran 15
Bari 13
Guangzhou 13
Mascalucia 13
Redondo Beach 13
Bernareggio 12
Brno 12
Bronte 12
City of London 12
Fortaleza 12
Totale 15.292
Salva come PNG Salva come JPEG
Nome #
Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy 301
Childhood neurofibromatosis type 2 (NF2) and related disorders: From bench to bedside and biologically targeted therapies [Neurofibromatosi tipo 2 (NF2) e sindromi correlate in età infantile: dalla biologia molecolare alla pratica clinica e nuove terapie con farmaci biologici] 286
α-Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron Overload 236
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment 222
Lactate accumulation promotes immunosuppression and fibrotic transformation of bone marrow microenvironment in myelofibrosis 220
Inhibition of TLR4 signaling affects mitochondrial fitness and overcomes bortezomib resistance in myeloma plasma cells 209
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 206
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection 204
Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM) 203
"MESENTERIUM COMMUNE" IN GIOVANE ADULTO. UN RARO CASO CLINICO 189
Focus on Osteosclerotic Progression in Primary Myelofibrosis 189
A Reciprocal Link between Oral, Gut Microbiota during Periodontitis: The Potential Role of Probiotics in Reducing Dysbiosis-Induced Inflammation 184
A Phase III Study of Enoxaparin Vs Aspirin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Lenalidomide-Based Regimen 184
Heme oxygenase-1 nuclear translocation regulates bortezomib-induced cytotoxicity and mediates genomic instability in myeloma cells. 183
Ixazomib improves bone remodeling and counteracts sonic hedgehog signaling inhibition mediated by myeloma cells 183
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab 169
Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno-microenvironment in multiple myeloma 168
Hedgehog signaling pathways in multiple myeloma 168
NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) IMPROVES THE RISK ASSESSMENT OF ISS STAGING IN NEWLY DIAGNOSED MM PATIENTS TREATED UPFRONT WITH NOVEL AGENTS 168
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 167
High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling 163
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy via STAT3 162
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases 161
Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells. 161
A case of high-risk AML in a patient with advanced systemic mastocytosis 160
Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia 158
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 156
Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells 154
A snapshot of asparaginase-induced liver insufficiency. 153
A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents 152
Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma 151
Absolute Count of Myeloid Derived Suppressor Cells (MDSC) Is Able to Predict the Response to Early-PET In Hodgkin Lymphoma 150
Myeloma Patient With Brugada Syndrome and Successful Lenalidomide Treatment 149
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib 149
Acute GVHD after allogeneic hematopoietic transplantation affects early marrow reconstitution and speed of engraftment 148
Immune Response and Breakthrough Infection Risk After SARS-CoV-2 Vaccines in Patients with Hemoglobinopathy: A Single Center Experience 147
Analysis of metabolic parameters coming from basal and interim PET in hodgkin lymphoma 147
Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over 146
BORTEZOMIB INHIBITS OSTEOCLASTOGENESIS AND MODULATE CHIT1 AND YKL40 EXPRESSION 146
ARGINASE 1 IS A MARKER OF MYELOID-MEDIATED IMMUNOSUPPRESSION WITH PROGNOSTIC MEANING IN CLASSIC HODGKIN'S LYMPHOMA 145
Clinical impact of the immunome in lymphoid malignancies: the role of Myeloid-Derived Suppressor Cells 145
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy 145
Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib 144
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients 143
TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma 143
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 142
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine 140
Mesenchymal stem cells (MSC) promotes tumor microenvironment transformation driving Granulocyte-like Myeloid Derived Suppressor Cells (G-MDSC) activation in Smoldering and Multiple Myeloma patients 140
Multiple Myeloma in 2023 Ways: From Trials to Real Life 138
Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma Network 137
Saprochete capitata: Emerging Infections from Uncommon Microorganisms in Hematological Diseases 137
Correction: TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma (Cell Death & Disease, (2019), 10, 10, (704), 10.1038/s41419-019-1959-5) 135
Bone turnover markers in patients with type 1 Gaucher disease 135
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: A phase III, open-label, randomized trial 135
CIRCULATING ARGINASE-1 IN SERUM IS A NOVEL BIO-MARKERIN HODGKIN LYMPHOMA 132
A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones? 132
CD200 EXPRESSION ON MYELOMA CELLS AND ANTITUMOR IMMUNITY 131
Efficacy and safety of tixagevimab-cilgavimab versus SARS-CoV-2 breakthrough infection in the hematological conditions 130
Engagement of Mesenchymal Stromal Cells in the Remodeling of the Bone Marrow Microenvironment in Hematological Cancers 129
Carbon nanotube-based sensing devices for human Arginase-1 detection 128
The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents 126
Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study 124
The Role of Dielectrophoresis for Cancer Diagnosis and Prognosis 124
Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey 123
CD200 expression in patients with multiple myeloma: Another piece of the puzzle 123
MacroH2A1.1 as a crossroad between epigenetics, inflammation and metabolism of mesenchymal stromal cells in myelodysplastic syndromes 122
Abnormal F-18 fluorodeoxyglucose uptake of the lung in immunocompromised lymphoma patients in complete remission: Report of two cases and revision of literature 122
Label-Free Enrichment of Circulating Tumor Plasma Cells: Future Potential Applications of Dielectrophoresis in Multiple Myeloma 121
Advanced Stage Hodgkin Lymphoma: Patient Management 121
The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis 120
Single segment of spleen autotransplantation, after splenectomy for trauma, can restore splenic functions 120
Role of Serum Free Light Chain Assay in Relapsed/Refractory Multiple Myeloma. A Real-Life Unicentric Retrospective Study 118
Addressing Non-linear System Dynamics of Single-Strand RNA Virus-Host Interaction 118
Advances in understanding regulatory myeloid cells 118
HIGH-RESOLUTION SNP ARRAYS AS AN ADDITIONAL TOOL TO SEARCH FOR GENETIC DEFECTS INVOLVED IN PROGRESSION FROM MYELODYSPLASTIC SINDROME TO ACUTE LEUKEMIA 115
Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future 114
Proteomic analysis reveals autophagy as pro-survival pathway elicited by long-term exposure with 5-azacitidine in high-risk myelodysplasia 114
Endoscopic features of gastro-intestinal lymphomas: From diagnosis to follow-up 114
Serum free light chains and multiple myeloma: Is it time to extend their application? 113
IGFBP-6/sonic hedgehog/TLR4 signalling axis drives bone marrow fibrotic transformation in primary myelofibrosis 113
Mitochondrial Bioenergetics at the Onset of Drug Resistance in Hematological Malignancies: An Overview 113
Immunological Subsets Characterization in Newly Diagnosed Relapsing–Remitting Multiple Sclerosis 112
Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study 111
Broad copy neutral-loss of heterozygosity regions and rare recurring copy number abnormalities in normal karyotype-acute myeloid leukemia genomes 110
Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients 109
Impact of buffer composition on biochemical, morphological and mechanical parameters: A tare before dielectrophoretic cell separation and isolation 108
NEUTROPHIL TO LYMPHOCYTE RATIO IMPROVES THE RISK ASSESSMENT OF ISS STAGING IN NEWLY DIAGNOSED MM PATIENTS TREATED UPFRONT WITH NOVEL AGENTS 108
SMOLDERING MYELOMA: WALKING THROUGH RISK FACTORS AND TENTATIVE CLASSIFICATION SYSTEMS 105
Aplastic Anemia & MDS International Foundation (AA&MDSIF): Bone marrow failure disease scientific symposium 2012 103
TLR4 Signaling and Heme Oxygenase-1/Carbon Monoxide Pathway Crosstalk Induces Resiliency of Myeloma Plasma Cells to Bortezomib Treatment 102
Monocytic Myeloid Derived Suppressor CELLS (M-MDSC) As Prognostic Factor in Chronic Myeloid Leukemia Patients Treated with Dasatinib 102
IMATINIB INCREASES CYTOTOXICITY OF MELPHALAN AND DECREASES PROLONGATION OF G2-M PHASE IN HUMAN K562 CELLS 102
Rate of fungal infections in patients with acute myeloid leukemia during induction treatment performing two prophylactic strategies: preliminary results 102
Multicentric Castleman disease and concurrent hematological disorders: the occurrence of plasmacytoma and the hypotheses arising from literature's review 101
Detection of fungal dna in lysis-centrifugation blood culture for the prevision of response to antifungal in aml patients with persistent neutropenic fever: a pilot subset 101
Bortezomib induced expression of heme oxygenase 1 via endoplasmic reticulum stress 19th Congress of the European-Hematology-Association. Milan, ITALY. Jun 12-15, 2014. 99
Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection 99
BROAD COPY NEUTRAL-LOSS OF HETEROZYGOSITY REGIONS AND RARE RECURRING COPY NUMBER ABNORMALITIES IN KARYOTYPICALLY NORMAL ACUTE MYELOID LEUKEMIA GENOMES 98
Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma 97
Heme oxygenase 1 (HO-1) protects myeloma cells against bortezomib through nuclear translocation and regulation of ER stress and autophagy proteins. 96
Totale 14.299
Salva come PNG Salva come JPEG
Categoria #
all - tutte 78.285
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 78.285
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022982 0 151 8 11 190 21 153 60 102 16 33 237
2022/20232.113 157 114 31 131 229 362 9 363 522 34 108 53
2023/20241.339 59 195 74 105 70 295 31 104 9 32 217 148
2024/20254.574 57 736 287 216 943 508 150 208 334 381 354 400
2025/202610.804 625 1.173 1.659 728 1.592 2.039 1.080 235 570 637 286 180
2026/2027609 224 385 0 0 0 0 0 0 0 0 0 0
Totale 22.860